Literature DB >> 28874423

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.

Ben A Kappel1, Michael Lehrke1, Katharina Schütt1, Anna Artati1, Jerzy Adamski1, Corinna Lebherz1, Nikolaus Marx2.   

Abstract

Entities:  

Keywords:  SGTL2 inhibitors; branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; type 2 diabetes mellitus

Mesh：

Substances：

Year:  2017        PMID： 28874423     DOI： 10.1161/CIRCULATIONAHA.117.029166

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  35 in total

Review 1.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 2.  [Microbiome, diabetes and heart: a novel link?]

Authors:  B A Kappel; M Lehrke
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

Review 3.  Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.

Authors:  Adriana Marton; Tatsuroh Kaneko; Jean-Paul Kovalik; Atsutaka Yasui; Akira Nishiyama; Kento Kitada; Jens Titze
Journal:  Nat Rev Nephrol       Date:  2020-10-01       Impact factor: 28.314

Review 4.  Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis.

Authors:  Deirdre K Tobias; Samia Mora; Subodh Verma; Patrick R Lawler
Journal:  Curr Opin Cardiol       Date:  2018-09       Impact factor: 2.161

Review 5.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

Review 6.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.

Authors:  Xiaodan Wang; Jingyu Ni; Rui Guo; Lan Li; Jing Su; Feng He; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2021-03-12       Impact factor: 4.214

7.  Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.

Authors:  Xuan Li; Qingguo Lu; Yunguang Qiu; Jussara M do Carmo; Zhen Wang; Alexandre A da Silva; Alan Mouton; Ana C M Omoto; Michael E Hall; Ji Li; John E Hall
Journal:  J Am Heart Assoc       Date:  2021-03-13       Impact factor: 5.501

Review 8.  Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Konstantinos E Iliodromitis; Sotiria G Giotaki; Charalampos Kossyvakis; Konstantinos Raisakis; Andreas Kaoukis; Vaia Lambadiari; Dimitrios Avramides; Bernhard Reimers; Giulio G Stefanini; Michael Cleman; Georgios Giannopoulos; Alexandra Lansky; Spyridon G Deftereos
Journal:  Drugs       Date:  2021-07-23       Impact factor: 9.546

Review 9.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 10.  Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes.

Authors:  Gabriela Dumitrita Stanciu; Razvan Nicolae Rusu; Veronica Bild; Leontina Elena Filipiuc; Bogdan-Ionel Tamba; Daniela Carmen Ababei
Journal:  Biomedicines       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.